Antiseizure medicines are not interchangeable. A drug that works well for one seizure type can be less effective—or occasionally worsen seizures—in another.
This is why accurate seizure classification matters before treatment is chosen.
The first question: focal or generalised?
One of the most important treatment distinctions is whether seizures begin in a focal brain network or are generalised from onset.
Some broad-spectrum medicines can treat both. Others are much better suited to focal epilepsy.
Focal seizures
Medicines commonly used for focal seizures include lamotrigine, levetiracetam, carbamazepine, oxcarbazepine, lacosamide, zonisamide and others.
Exact first-line choices differ between countries and age groups.
Generalised tonic-clonic seizures
Broad-spectrum medicines are usually preferred when seizures are generalised or when the epilepsy type is not yet certain.
Options may include levetiracetam, lamotrigine, valproate, topiramate and others depending on the person’s circumstances and local approvals.
Absence seizures
Ethosuximide is highly effective for typical absence seizures when absence is the only seizure type.
If other generalised seizure types are also present, a broader-spectrum medicine may be needed.
Myoclonic seizures
Some sodium-channel-focused medicines that are excellent treatments for focal seizures can aggravate myoclonic seizures.
Examples include carbamazepine and oxcarbazepine.
Medicines can worsen the wrong seizure type
Current treatment guidance warns that carbamazepine, oxcarbazepine, phenytoin, gabapentin, pregabalin, tiagabine and vigabatrin can worsen certain absence or myoclonic seizures.
Lamotrigine can occasionally worsen myoclonus in some people.
Syndrome matters too
Treatment is not chosen only from seizure type.
Dravet syndrome, Lennox–Gastaut syndrome, infantile epileptic spasms syndrome and other named epilepsies have syndrome-specific evidence and treatment priorities.
Cause can change treatment
A metabolic or genetic diagnosis may alter treatment choice.
Examples include ketogenic therapy in GLUT1 deficiency, vitamin B6 treatment in pyridoxine-dependent epilepsy and avoidance or preference of particular sodium-channel medicines in selected channelopathies.
Age matters
Evidence, licensing and side-effect profiles differ between infants, children, adolescents, adults and older people.
Pregnancy potential matters
Some antiseizure medicines carry important reproductive risks.
Valproate has major fetal risks and is subject to strict restrictions in many jurisdictions. Topiramate and other medicines also require reproductive-risk assessment.
Comorbidities matter
Clinicians consider mood, cognition, migraine, body weight, kidney or liver disease, osteoporosis risk, cardiac disease and other conditions when selecting treatment.
Other medicines matter
Drug interactions can make an otherwise reasonable antiseizure medicine a poor choice.
Enzyme-inducing drugs can interact with contraceptives, anticoagulants and many other medicines.
Monotherapy is usually preferred first
Where possible, clinicians generally begin with one appropriately chosen medicine and increase it gradually.
If it fails because of lack of efficacy or adverse effects, another monotherapy or rational add-on treatment may be tried.
Failure of two appropriate medicines
Failure of two tolerated, appropriately chosen and adequately used antiseizure medication schedules to achieve sustained seizure freedom meets the standard concept of drug-resistant epilepsy.
At that point, surgery and other non-drug treatments should be considered rather than simply cycling indefinitely through medicines.
Guidelines differ
Specific first-line rankings vary between national guidelines because approvals, pregnancy rules, cost and evidence interpretation differ.
The underlying principle is global: match treatment to seizure type, epilepsy type or syndrome, cause and the individual person.
The central point
The “best epilepsy medicine” does not exist in isolation. The best option is the one that fits the seizure type and syndrome while balancing effectiveness, side effects, interactions and the person’s circumstances.
Related reading
Treatment Options →
Drug-Resistant Epilepsy →
Drug Interactions Between Antiseizure Medicines →
Sources
- NICE NG217 — seizure-specific antiseizure treatment (UK-specific prescribing guidance)
- NICE NG217 — treatment principles
Global note: drug licensing, first-line choices and reproductive-safety rules vary by country. The examples above illustrate seizure-specific principles and are not a prescription.
Evidence checked: September 2026.